Identify and quantify dd-cfDNA for post-transplant monitoring
After a solid organ transplant, monitoring levels of dd-cfDNA can provide valuable insights into the organ's health and function. Allowing your laboratory to perform these tests on-site can empower your transplant program and provide better turnaround times for results. One Lambda™ Devyser™ Accept cfDNA, a non-invasive, cutting-edge single-tube NGS assay, provides precise and reliable results, enabling effective post-transplant monitoring and early detection of allograft injury.
Accept cfDNA is an NGS assay designed to detect and analyze circulating dd-cfDNA in post-transplant human plasma samples. Its unique indel design allows for accurate discrimination between two genetically distinct donors per -recipient and reduces amplification and sequencing errors. Combined with an efficient workflow, Accept cfDNA is the ideal tool for post-transplant monitoring and early detection of graft injury.
The One Lambda Devyser Accept cfDNA assay was developed in conjunction with a nephrologist to deliver efficiency and ease of use with minimal hands-on time. Labs can receive next-day results from sample to report allowing for timely and accurate diagnoses that can improve clinician decision-making. Our dedicated software simplifies data analysis and bioinformatics capabilities, allowing for easy patient tracking in a single location. With the ability to import analysed data into Histotrac, all information is consolidated, providing clear visibility of trends.
The partnership between Devyser and Thermo Fisher Scientific combines expertise and resources to offer enhanced and cutting-edge molecular transplant monitoring capabilities to transplant programs, HLA labs, and transplant clinicians. Backed by Thermo Fisher Scientific's robust commercial infrastructure, our collaboration ensures reliable, accurate, and high-quality testing solutions for healthcare providers worldwide.
Product is CE marked but not 510(k)-cleared and not available for sale in the U.S. Availability of product in each country depends on local regulatory marketing authorization status.